Deal conducted by HDL Capital; units include five-year C$0.50 warrants
By Devika Patel
Knoxville, Tenn., April 1 – Helix BioPharma Corp. said it increased a private placement of units to C$9.1 million and settled the sale. The deal priced for C$5.2 million on March 16.
The company sold units of one common share and one warrant at C$1.10 per unit.
Each five-year warrant is exercisable at C$1.54, a 3.75% discount to C$1.60, the March 13 closing share price.
Helix BioPharma is an Aurora, Ont., biopharmaceutical company developing products for the treatment of cancer and pre-cancerous conditions.
| Issuer: | Helix BioPharma Corp.
|
| Issue: | Units of one common share and one warrant
|
| Amount: | C$9.1 million
|
| Price: | C$1.10
|
| Warrants: | One warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | C$1.54
|
| Pricing date: | March 16
|
| Upsized: | April 1
|
| Settlement date: | April 1
|
| Stock symbol: | Toronto: HBP
|
| Stock price: | C$1.60 at close March 13
|
| Market capitalization: | C$144.3 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
